Rathbones Group PLC Has $24.81 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Rathbones Group PLC grew its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 7.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 109,334 shares of the medical instruments supplier's stock after acquiring an additional 7,737 shares during the quarter. Rathbones Group PLC's holdings in Becton, Dickinson and Company were worth $24,805,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in BDX. Principal Financial Group Inc. grew its position in shares of Becton, Dickinson and Company by 1.5% during the 3rd quarter. Principal Financial Group Inc. now owns 1,179,715 shares of the medical instruments supplier's stock valued at $284,429,000 after buying an additional 16,918 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Becton, Dickinson and Company by 4.2% during the third quarter. Janus Henderson Group PLC now owns 45,947 shares of the medical instruments supplier's stock worth $11,077,000 after acquiring an additional 1,843 shares during the last quarter. Integrated Wealth Concepts LLC increased its holdings in shares of Becton, Dickinson and Company by 75.3% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 4,730 shares of the medical instruments supplier's stock worth $1,140,000 after acquiring an additional 2,031 shares during the period. Quantinno Capital Management LP lifted its position in Becton, Dickinson and Company by 26.3% in the 3rd quarter. Quantinno Capital Management LP now owns 7,690 shares of the medical instruments supplier's stock valued at $1,854,000 after purchasing an additional 1,599 shares during the last quarter. Finally, MML Investors Services LLC boosted its stake in Becton, Dickinson and Company by 51.8% during the 3rd quarter. MML Investors Services LLC now owns 62,762 shares of the medical instruments supplier's stock valued at $15,132,000 after purchasing an additional 21,427 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Remove Ads

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the company's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the sale, the executive vice president now directly owns 5,741 shares of the company's stock, valued at approximately $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 597 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $236.51, for a total transaction of $141,196.47. Following the completion of the transaction, the executive vice president now directly owns 5,544 shares in the company, valued at approximately $1,311,211.44. This trade represents a 9.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,675 shares of company stock worth $1,057,182. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Price Performance

NYSE BDX traded up $2.42 on Friday, reaching $201.54. 1,850,652 shares of the stock traded hands, compared to its average volume of 1,688,275. Becton, Dickinson and Company has a 12 month low of $193.03 and a 12 month high of $251.99. The company has a market cap of $57.87 billion, a price-to-earnings ratio of 33.48, a P/E/G ratio of 1.63 and a beta of 0.35. The firm's fifty day simple moving average is $223.97 and its 200 day simple moving average is $229.81. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has authorized a stock repurchase program on Tuesday, January 28th that permits the company to buyback 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company's board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 10th were paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.06%. The ex-dividend date of this dividend was Monday, March 10th. Becton, Dickinson and Company's dividend payout ratio is presently 69.10%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on BDX shares. StockNews.com raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, April 2nd. Piper Sandler lifted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an "overweight" rating in a research note on Tuesday, January 28th. Finally, Barclays decreased their price target on Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating for the company in a research note on Monday, April 7th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $275.71.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.